Recent studies have demonstrated that tumor neoantigens can be derived de novo from the expression of genetic mutations and presented in major histocompatibility complexes (MHC) on tumor cells, and endogenous T cell responses against neoantigens can be naturally activated in cancer patients1–4. Here, HLA-C is linked to neoplasm.